CRISPR-Cas系统通过DNA切割（Cas9）、RNA靶向（Cas13a）及噬菌体疗法实现精准消除产超广谱β-内酰胺酶肠杆菌科（CRE）的耐药基因，临床前研究验证其疗效，但递送效率、宿主范围及生态风险仍需优化，未来需结合新型递送平台（如外膜囊泡、纳米颗粒）与伦理监管 ...

Last year, a ten-month-old baby in the US was the first person in the world to have their rare genetic disease effectively ...

AI‑driven protein design creates potent anti‑CRISPR inhibitors that block Cas13 activity, offering a new potential tool for safer, more controlled gene editing.

The recent clinical success of treating “Baby KJ” Muldoon—an infant born with a rare metabolic disease—with the first-ever personalized gene-editing therapy brought much-needed enthusiasm to the ...